Drug intelligence / Profile preview

Romi-Multiplat

Development stage: Preclinical
Lead developer: PARAS Biopharma
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Romi-Multiplat (PB(CT)-4020) is a romiplostim biosimilar being developed by Paras Biopharmaceuticals Finland Oy. It is a recombinant protein peptibody that acts as a thrombopoietin (TPO) receptor agonist, stimulating megakaryocyte proliferation and platelet production. The drug is intended for the treatment of chronic immune thrombocytopenic purpura (ITP) and other platelet disorders, including those associated with oncology treatments. It is produced using a proprietary continuous manufacturing technology and is currently in preclinical development.

Brand names: Romi-Multiplat
Other names: romiplostim biosimilarPB(CT)-4020

Targets

TPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on Romi-Multiplat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Romi-Multiplat.

Explore the full profile